|
|
Vaccine Detail
|
NEO-PV-01 vaccine |
| Vaccine Information |
- Vaccine Name: NEO-PV-01 vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor specific neoantigen (NCT03166254; NCIT_C129935)
- Immunization Route: Other
- Description: This is a synthetic peptide-based, personalized cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. (NCIT_C129935) Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number of altered proteins that can be recognized as foreign by the immune system. Targeting the immune system against tumor specific antigens using a peptide vaccine could lead to improved response rate and prolonged overall survival with no additional toxicity when combined with Pembrolizumab (monoclonal antibodies that block PD-1/PD-L1 interactions) and standard of care chemotherapy. (NCT03166254)
|
| Host Response |
|
|
| References |
NCIT_C129935: Personalized Peptide Cancer Vaccine NEO-PV-01 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129935]
NCT03166254: Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer [https://clinicaltrials.gov/study/NCT03166254]
|
|
